6492.TWO Senhwa Biosciences, Inc.
- Market cap
- TWD 3.32B
- P/E
- -
- P/B
- 5.67x
- ROE
- -48.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6492.TWO undervalued?
Graham numberThe Graham number of Senhwa Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Senhwa Biosciences, Inc. fundamental analysis
No fundamental analysis for Senhwa Biosciences, Inc. yet.
Senhwa Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, …
Full company profileSenhwa Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Senhwa Biosciences, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 550K | 1.00M | 1.00M | 1.00M | 1.07M | 960K |
| Gross Profit | 323K | 505K | 552K | 477K | 520K | 540K |
| Operating Income | -346M | -356M | -311M | -306M | -278M | -307M |
| EBITDA | - | -341M | -284M | -280M | -251M | -287M |
| Net Income | -329M | -350M | -296M | -294M | -265M | -299M |
| EPS | -3.69 | -3.86 | -3.27 | -3.24 | -2.91 | -3.29 |
| Balance Sheet | ||||||
| Total Assets | 2.06B | 1.65B | 1.36B | 1.07B | 819M | 679M |
| Total Liabilities | 92.4M | 40.9M | 46.2M | 38.9M | 58.3M | 62.6M |
| Shareholders' Equity | 1.97B | 1.61B | 1.32B | 1.03B | 761M | 617M |
| Cash & Short-term Investments | 2.03B | 1.62B | 1.32B | 1.03B | 772M | 637M |
| Cash Flow | ||||||
| Operating Cash Flow | -300M | -400M | -294M | -294M | -248M | -266M |
| Capital Expenditure | 401K | 369K | 4.77M | 1.95M | 280K | 776K |
| Free Cash Flow | -300M | -400M | -299M | -296M | -249M | -266M |
| Ratios | ||||||
| ROE | -16.7% | -21.7% | -22.5% | -28.6% | -34.8% | -48.4% |
| ROA | -16.0% | -21.1% | -21.7% | -27.6% | -32.3% | -44.0% |
| Net Profit Margin | -59,864.9% | -34,963.2% | -29,630.6% | -29,374.5% | -24,744.8% | -31,110.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Senhwa Biosciences, Inc. dividends
Senhwa Biosciences, Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 477.33:1000 on Mar 16, 2020.
Who owns Senhwa Biosciences, Inc.
- Insiders 22.86%
- Institutions 0.00%
- Public & others 77.14%
- Shares outstanding 114M
- Free float 67.4M
Senhwa Biosciences, Inc. company profile
- Company name
- Senhwa Biosciences, Inc.
- Ticker
- 6492.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 225, Peihsin Road, New Taipei City, Taiwan, 23143
- Phone
- 886 2 8911 9856
- Website
- senhwabio.com
About Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.
Senhwa Biosciences, Inc. management
3- Ms. Sarah Chang CPAExecutive VP, CFO & Accounting Supervisor
- Mr. Jason Huang M.D.Acting CEO & Chief Medical Officer
- Ms. Joanne Lo Ph.D.Acting Chief Operating Officer & Business Development Director